Adherence, persistence and treatment switching in psoriasis

References

• Samarasekera EJ, Neilson JM, Warren RB et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346. doi:10.1038/jid.2013.149
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S. More than skin-deep: the many dimensions of the psoriatic disease. Swiss Med Wkly 2014;144:w13968. doi:10.4414/smw.2014.13968
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, Wakkee M, Arends LR et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542–1551. doi:10.1038/jid.2013.508
   PubMed Web of Science ®Google Scholar
• Kolios AG, Yawalkar N, Anliker M et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology 2016;232(4):385–406. doi:10.1159/000445681
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work G, Menter A, Korman NJ et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174. doi:10.1016/j.jaad.2010.11.055
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Romiti R, Tebbey PW. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin. 2015;33(1):111–125. doi:10.1016/j.det.2014.09.009
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two Phase III trials. New England J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Armstrong A, Fahrbach K, Leonardi C et al. Efficacy of bimekizumab and other biologics in moderate-to-severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther. (Heidelb) 2022;12(8):1777–1792. doi:10.1007/s13555-022-00760-8
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate-to-severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. doi:10.1016/j.jaad.2015.03.049
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Menter A, Gelfand JM, Connor C et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi:10.1016/j.jaad.2020.02.044
   PubMed Web of Science ®Google Scholar
• Augustin M, Kleyn CE, Conrad C et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35(1):123–134. doi:10.1111/jdv.16431
   PubMed Web of Science ®Google Scholar
• Ozkok Akbulut T, Topaloglu Demir F, Oguz Topal I et al. Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study. Int J Dermatol. 2021;60(9):1140–1147. doi:10.1111/ijd.15628
   PubMed Web of Science ®Google Scholar
• Ismail N, Collins P, Rogers S et al. Drug survival of fumaric acid esters for psoriasis: a retrospective study. British J Dermatol. 2014;171(2):397–402. doi:10.1111/bjd.12849
   PubMed Web of Science ®Google Scholar
• Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13(7):848–853.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value in Health 2008;11(1):44–47. doi:10.1111/j.1524-4733.2007.00213.x
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. British J Dermatol. 2011;164(5):1091–1096. doi:10.1111/j.1365-2133.2011.10213.x
   PubMed Web of Science ®Google Scholar
• Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117–122. doi:10.15386/mpr-1201
   PubMedGoogle Scholar
• Vrijens B, De Geest S, Hughes DA et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167
   PubMed Web of Science ®Google Scholar
• Leonardi C, Zhu B, Malatestinic WN et al. Real-world biologic adherence, persistence, and monotherapy comparisons in US patients with psoriasis: results from IBM MarketScan((R)) databases. Advan Ther. 2022;39(7):3214–3224. doi:10.1007/s12325-022-02155-9
   PubMed Web of Science ®Google Scholar
• Belinchon I, Rivera R, Blanch C et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adher. 2016;10:2357–2367. doi:10.2147/PPA.S117006
   PubMed Web of Science ®Google Scholar
• Doshi JA, Takeshita J, Pinto L et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–65 e4. doi:10.1016/j.jaad.2016.01.048
   PubMed Web of Science ®Google Scholar
• Huang YH, Tang CH, Goh CH et al. Persistence and adherence to biologics in patients with psoriasis in Taiwan: a new biologics user cohort study. Front Pharmacol. 2022;13:880985. doi:10.3389/fphar.2022.880985
   PubMed Web of Science ®Google Scholar
• Piragine E, Petri D, Martelli A et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med. 2022;11(6):1506 doi:10.3390/jcm11061506
   PubMed Web of Science ®Google Scholar
• Yiu ZZN, Becher G, Kirby B et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. doi:10.1001/jamadermatol.2022.2909
   PubMed Web of Science ®Google Scholar
• Costanzo A, Malara G, Pelucchi C et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology 2018;234(1–2):1–12. doi:10.1159/000488586
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R et al. Drug Survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi:10.1007/s40257-021-00598-4
   PubMed Web of Science ®Google Scholar
• Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8(1):16068. doi:10.1038/s41598-018-34293-y
   PubMedGoogle Scholar